Streetbeat News

ALLR

Allarity Therapeutics, Inc.

https://www.allarity.com

Industry

Biotechnology

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Allarity Therapeutics has postponed its Annual Meeting of Stockholders, which was originally scheduled for July 26, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 1:03 pm

General Dynamics Corporation (NYSE:GD) shares fell 5.2% after reporting worse-than-expected Q2 EPS results despite revenue growth. Other notable stock movements include significant gains for NuZee, Inc. (NASDAQ:NUZE) and Dermata Therapeutics, Inc. (NASDAQ:DRMA), and declines for Azitra, Inc. (NYSE:AZTR) and Tesla, Inc. (NASDAQ:TSLA).

Portfolio Pulse from Avi Kapoor

July 24, 2024 | 5:26 pm

Enphase Energy shares rose 6.2% in pre-market trading despite missing Q2 revenue and earnings estimates. Other notable pre-market movers include Dermata Therapeutics, NuZee, Regencell Bioscience, Allarity Therapeutics, NewGenIvf Group, Perfect Moment, ENGlobal Corporation, 1847 Holdings, and Seagate Technology among gainers, while Azitra, Conn’s, Verastem, ATI Physical Therapy, Volato Group, Chijet Motor, AtlasClear Holdings, Wheels Up Experience, SFL Corporation, and Tesla saw declines.

Portfolio Pulse from Avi Kapoor

July 24, 2024 | 9:27 am

Allarity Therapeutics has reported its progress and objectives for 2024 in a recent SEC filing. The company outlined key milestones and strategic goals aimed at advancing its therapeutic pipeline.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:48 pm

Allarity Therapeutics Inc (NASDAQ:ALLR) received a Wells Notice from the SEC regarding disclosures about their NDA for Dovitinib. The notice suggests potential legal action but is not a formal charge. The company plans to respond formally and has proposed a reverse stock split to regain NASDAQ compliance. Allarity will focus on advancing stenoparib and has a financial runway extending into 2026.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 4:30 pm

Allarity Therapeutics received a Wells Notice from the SEC regarding its disclosures about meetings with the FDA concerning its NDA for Dovitinib or Dovitinib-DRP. The company has a cash balance of $20 million, expected to last until 2026, and has paused its ATM usage. Additionally, Allarity's Stenoparib shows extended Phase 2 clinical benefits.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:02 pm

Allarity Therapeutics received a Wells Notice from the SEC regarding its 2021 FDA NDA submission for Dovitinib. The notice suggests potential enforcement action for alleged securities law violations. The company and three former officers are implicated, but Allarity plans to respond formally.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 10:22 am

ASLAN Pharmaceuticals shares dropped over 38% after announcing the voluntary liquidation of its sole operating subsidiary. Other notable stock movements include Aptevo Therapeutics climbing 84% following a $2.75 million offering, and Shimmick Corporation rising 49% after securing a $27.6 million subcontract. Cassava Sciences fell nearly 30% due to executive leadership changes.

Portfolio Pulse from Avi Kapoor

July 17, 2024 | 5:28 pm

Allarity Therapeutics shares are trading higher after the company announced that it received notice from the NASDAQ Stock Market that it was granted a hearing.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:16 pm

Allarity Therapeutics (NASDAQ:ALLR) has been granted a hearing before a Nasdaq Hearings Panel to present its plan for regaining compliance with NASDAQ listing requirements.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.